We report a case of an anaplastic lymphoma kinase (ALK) fusion‐positive non‐small‐cell lung cancer patient who developed severe hemolytic anemia after starting low‐dose alectinib due to liver failure from diffuse liver metastasis. The gene discussed is ALK; the disease is Hepatic failure.